Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2007-01-02
2007-01-02
McKane, Joseph K. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C514S323000, C514S253050, C514S254090, C514S312000, C514S414000, C514S235200, C544S373000, C544S363000, C546S201000, C546S153000, C548S460000, C548S468000, C548S455000
Reexamination Certificate
active
10793952
ABSTRACT:
The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
REFERENCES:
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 6147106 (2000-11-01), Tang et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 6465507 (2002-10-01), Tang et al.
patent: 6486185 (2002-11-01), McMahon et al.
patent: 6573293 (2003-06-01), Tang et al.
patent: 6599902 (2003-07-01), Cui et al.
patent: 6706709 (2004-03-01), Tang et al.
patent: 6777417 (2004-08-01), Liang et al.
patent: 6797725 (2004-09-01), Sun et al.
patent: 6878733 (2005-04-01), Shenoy et al.
patent: 2002/0052369 (2002-05-01), Tang et al.
patent: 2002/0107040 (2002-08-01), Crandall et al.
patent: 2004/0063773 (2004-04-01), Tang et al.
patent: 2004/0266843 (2004-12-01), Howlett et al.
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 99/11605 (1999-03-01), None
patent: WO 01/37820 (2001-05-01), None
patent: WO 200160814 (2001-08-01), None
patent: WO 2003015608 (2003-02-01), None
Traxler, P., et al., “Tyrosine Kinase Inhibitors: From Rational Design to Clinical Trials,” Medicinal Research Reviews, vol. 21(6), pp. 499-512 (2001), at p. 505, line 14 to p. 507, line 6, and Figure 4.
Wang, X., et al., “Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth,” Molec. Cancer Ther., vol. 2(11), pp. 1085-1092 (Nov. 2003), at p. 1087.
Sun et al., J. Med. Chem. 1999, 42, 5120-5130.
Akbasak et al., “Oncogenes: cause or consequence in the development of glial tumors,”Journal of the Neurological Sciences, 1992, pp. 119-133, vol. 111, Elsevier Science Publishers B.V.
Arteaga et al., “Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,”J. Clin. Invest., Nov. 1989, pp. 1418-1423, vol. 84, The American Society for Clinical Investigation, Inc.
Arvidsson et al., “Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert Is Involved in GRB2 Binding and Ras Activation,”Molecular and Cellular Biology, Oct. 1994, pp. 6715-6726, vol. 14, No. 10.
Baserga et al., “Oncogenes and the Strategy of Growth Factors,”Cell, Dec. 16, 1994, pp. 927-930, vol. 79.
Baserga et al., “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research, Jan. 15, 1995, pp. 249-252, vol. 55.
Bolen et al., “Nonreceptor tyrosine protein kinases,”Oncogene, Aug. 1993, pp. 2025-2031, vol. 8, No. 8, Macmillan Press Ltd.
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB, Dec. 1992, pp. 3403-3409, vol. 6, No. 15.
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”Int. J. Cancer, Jun. 19, 1993, pp. 571-577, vol. 54, Wiley-Liss, Inc.
Chernikova et al., “Wortmannin Sensitizes Mammalian Cells to Radiation by Inhibiting the DNA-Dependent Protein Kinase-Mediated Rejoining of Double-Strand Breaks,”Radiation Research, 1999, pp. 159-166, vol. 151, Radiation Research Society.
Claesson-Welsh, “Signal Transduction by the PDGF Receptors,”Progress in Growth Factor Research, 1994, pp. 37-54, vol. 5, Elsevier Science Ltd.
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology, Jul. 1994, pp. 4588-4595, vol. 14, No. 7, American Society for Microbiology.
Eng et al., “Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? ”Kidney International, Feb. 1994, pp. S45-S47, vol. 45, Supplement 45, Blackwell Scientific Publications.
Eriksson et al., “DNA-Dependent Protein Kinase Is Inhibited by Trifluoperazine,”Biochemical and Biophysical Research Communications, 2001, pp. 726-731, vol. 283, Academic Press.
Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways,”Cell, May 1, 1992, pp. 413-423, vol. 69, No. 3, Cell Press.
Fingl et al., “General Principles,”The Pharmacological Basics of Therapeutics, 5thEdition, 1975, Section I, Chapter 1, pp. 1-46, Macmillan Publishing Co., Inc.
Folkman et al., “Angiogenesis,”The Journal of Biological Chemistry, Jun. 5, 1992, pp. 10931-10934, vol. 267, No. 16, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Folkman, “What is the Evidence that Tumors are Angiogenesis Dependent,”Journal of the National Cancer Institute, Jan. 3, 1990, pp. 4-6, vol. 82, No. 1.
Gennaro (Ed.),Remington: The Science and Practice of Pharmacy, 20thEdition, 2000, University of the Sciences in Philadelphia, Table of Contents Only.
Goldring et al., “Cytokines and Cell Growth Control,”Critical Reviews in Eukatyotic Gene Expression, 1991, pp. 301-326, vol. 1, Issue 4, CRC Press, Inc.
http://www.ncbi.nlm.nih.gov, P78527 “DNA-dependent protein kinase catalytic sub unit Accession P78527” (retrieved from Internet Sep. 1, 2004).
Hu et al., “Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,”Molecular and Cellular Biology, Mar. 1992, pp. 981-990, vol. 12, No. 3, American Society for Microbiology.
Izzard et al., “Competitive and Noncompetitive Inhibition of the DNA-dependent Protein Kinase,”Cancer Research, Jun. 1, 1999, pp. 2581-2586, vol. 59.
Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,”Biochemistry, Aug. 30, 1994, pp. 10450-10456, vol. 33, No. 34.
Kashishian et al., “Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cγ1,”Molecular Biology of the Cell, Jan. 1993, pp. 49-57, vol. 4, The American Society for Cell Biology.
Kashishian et al., “Phosphorylation sites in the PDGF receptor with difference specificities for binding GAP and PI3 kinasein vivo,”The EMBO Journal, 1992, pp. 1373-1382, vol. 11, No. 4.
Kazlauskas et al., “The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp,”Proc. Natl. Acad., Aug. 1993, pp. 6939-6942, vol. 90.
Kendall et al., “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,”Proc. Natl. Acad. Sci. USA, Nov. 1993, pp. 10705-10709, vol. 90.
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growthin vivo,”Nature, Apr. 29, 1993, pp. 841-844, vol. 362, No. 6423.
Kinsella et al., “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,”Experimental Cell Research, Mar. 1992, pp. 56-62, vol. 199, No. 1, Academic Press, Inc.
Klagsbrun et al., “VEGF/VPF: the angiogenesis factor found?”Current Biology, 1993, pp. 699-702, vol. 3, No. 10.
Koch et al., “SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,”Science, May
Liang Congxin
Lipson Kenneth E.
Miller Todd
Tang Peng Cho
Anderson Rebecca
Liptak Vincent P.
McKane Joseph K.
Sugen Inc.
Zielinski Bryan C.
LandOfFree
5-sulfonamido-substituted indolinone compounds as protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-sulfonamido-substituted indolinone compounds as protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-sulfonamido-substituted indolinone compounds as protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761279